Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Politics, Policy & Law

Oct. 11 Quick Takes: European Parliament proposes amendments to pharma legislation

Plus: Early stop for Novo’s kidney outcomes study of semaglutide; Agomab raises $100M series B; and updates from MinervaX, FDA, ARPA-H, Tempest, Kanvas-Federation Bio

October 12, 2023 12:27 AM UTC

The European Parliament’s Committee on the Environment, Public Health and Food Safety has posted a draft report with amendments to a European Commission proposal for the first major overhaul of European pharmaceutical law in 20 years, and amendments to an associated directive. Debate on the amendments could start next week.

Shares of dialysis providers sank Wednesday after Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO) said the Phase III FLOW kidney outcomes study of Ozempic semaglutide met criteria for an early stop due to efficacy. FLOW compared the once-weekly injectable drug with placebo in patients with Type II diabetes and chronic kidney disease. Novo gained 6% in New York, while shares of DaVita Inc. (NYSE:DVA) were off 17% and Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) lost 18%...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article